Her Majesty the Queen in Right of Canada, As Represented by the Minister of National Defence of Her Majesty's Canadian Government

Her Majesty the Queen in Right of Canada Represented by the Minister of National Defence of Her Majesty's Canadian Government

Bradley Berger

John Walter Cherwonogrodzky

Christopher Sikora

This invention discloses methods for identifyingvaccine candidates. It enables identification of novel vaccine candidates and quality assurance for vaccine batches, assessment of protection in vaccinates and identification of the infecting agent in vaccinates. Mice were first vaccinated withO-polysaccharide (OPS) vaccine. These animals were then given 10 LDs oflive vaccine strain (LVS). Sixty percent (60%) of the vaccinated mice survived the multiple lethal doses. Sera were collected from these surviving mice and the antibodies were used to probe supernatant and cell lysates of liveLVS cultures. Severalcomponents were identified only by the noted 'survivor' antisera. Of these identified proteins, enzyme digestions and chemical oxidation suggest post-translational modifications of some proteins e.g. a 52 kDa glycoprotein, a 45 kDa lipoprotein and a 19 kDa nucleoprotein. The 52 kDa component caused nitrous oxide induction in tissue cultures at low concentrations, cell death at high concentrations. Vaccination with this gave partial protection while addition of other components acted synergistically to give enhanced protection from 250 LDs ofLVS.

Growing community of inventors

CA

Bradley Berger